Wolverine Trading’s Akebia Therapeutics AKBA Stock Holding History

Wolverine Trading’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,198	Closed	-$25.9K	–	4425
2023 Q2	$18.7K	Buy	+20,198	New	+$19.5K	﹤0.01%	4102
2022 Q1	–	Sell	-12,536	Closed	-$29K	–	5330
2021 Q4	$29K	Buy	+12,536	New	+$34.2K	﹤0.01%	5456
2021 Q2	–	Sell	-27,071	Closed	-$91.1K	–	5796
2021 Q1	$84K	Sell	27,071 -316	-1%	-$1.14K	﹤0.01%	5497
2020 Q4	$82K	Buy	27,387 +7,995	+41%	+$23.3K	﹤0.01%	4515
2020 Q3	$46K	Buy	19,392 +7,358	+61%	+$64.6K	﹤0.01%	4286
2020 Q2	$153K	Buy	12,034 +1,587	+15%	+$16.4K	﹤0.01%	3968
2020 Q1	$83K	Sell	10,447 -9,515	-48%	-$74K	﹤0.01%	4095
2019 Q4	$131K	Buy	19,962 +4,430	+29%	+$21.1K	﹤0.01%	4204
2019 Q3	$64K	Sell	15,532 -517	-3%	-$2.22K	﹤0.01%	3996
2019 Q2	$78K	Buy	+16,049	New	+$91.3K	﹤0.01%	4092

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wolverine Trading's AKBA Position: Q3 2023 in Review

Wolverine Trading sold out of Akebia Therapeutics (AKBA) in Q3 2023, closing a stake of 20,198 shares — an estimated $25.9K sold.

Wolverine Trading first reported a position in AKBA in Q2 2019 and held it in 10 quarters. The position peaked at $153K in Q2 2020. 76 funds tracked by Wall St. Rank hold AKBA as of Q3 2023.

Wolverine Trading reported no remaining Akebia Therapeutics position as of Q3 2023 after selling out during the quarter.
Wolverine Trading sold 20,198 Akebia Therapeutics shares in Q3 2023, an estimated $25.9K.
Wolverine Trading first reported a position in Akebia Therapeutics in Q2 2019 and held it in 10 quarters.
Wolverine Trading's Akebia Therapeutics position peaked at $153K in Q2 2020.
76 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2023.

Based on Wolverine Trading's 13F filing for Q3 2023, filed 15 Nov 2023.